Literature DB >> 21912915

Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents.

Elif Kaya1, Alessandro Cuneo, Matthias Hochadel, Claus Jünger, Wibke Stepper, Peter Bramlage, Karl-Heinz Kuck, Christoph A Nienaber, Jochen Senges, Lars Eckardt, Ulrich Tebbe, Holger Reinecke.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) has an adverse impact on survival of patients with coronary artery disease and is associated with poor outcomes after percutaneous coronary intervention (PCI). Although small randomized, controlled clinical trials showed a reduced target vessel revascularization rate and a good safety profile for sirolimus-eluting coronary stents (SES), safety data need to be confirmed in clinical practice. Therefore, the data of the German DES.DE registry were evaluated to obtain acute and long-term data of this high-risk subgroup.
METHODS: The prospective multicenter German DES.DE registry enables to monitor the therapeutic outcome of different drug-eluting stents in the context of the German Health Care System. Baseline clinical and angiographic characteristics as well as one-year-follow-up data were recorded. From October 2005 to October 2006, 6,384 patients were enrolled at 98 DES.DE sites and stratified according to kidney disease progression: normal and impaired renal function and patients under chronic hemodialysis.
RESULTS: CKD was associated with several acute and chronic medical conditions and suffer from significantly more cardiac and cerebrovascular events after PCI as compared to patients without CKD. One-year-follow-up showed a significantly increased risk of restenosis and bleeding complications in patients with impaired renal function, especially in hemodialysis patients.
CONCLUSIONS: Impaired renal function in patients undergoing DES stenting carries an independent risk factor for restenosis and bleeding.

Entities:  

Mesh:

Year:  2011        PMID: 21912915     DOI: 10.1007/s00392-011-0347-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  25 in total

1.  Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial.

Authors:  Amir Halkin; Roxana Mehran; Christopher W Casey; Paul Gordon; Ray Matthews; B Hadley Wilson; Martin B Leon; Mary E Russell; Stephen G Ellis; Gregg W Stone
Journal:  Am Heart J       Date:  2005-12       Impact factor: 4.749

2.  Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Authors:  Christoph A Nienaber; Ibrahim Akin; Steffen Schneider; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Karl-Heinz Kuck
Journal:  Am J Cardiol       Date:  2009-09-26       Impact factor: 2.778

3.  Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.

Authors:  Thomas T Tsai; Thomas M Maddox; Matthew T Roe; David Dai; Karen P Alexander; P Michael Ho; John C Messenger; Brahmajee K Nallamothu; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-12-09       Impact factor: 56.272

4.  Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency.

Authors:  Asmir I Syed; Itsik Ben-Dor; Sara D Collins; Manuel A Gonzalez; Michael A Gaglia; Rebecca Torguson; Lowell F Satler; William O Suddath; Augusto D Pichard; Joseph Lindsay; Ron Waksman
Journal:  J Interv Cardiol       Date:  2010-02       Impact factor: 2.279

5.  Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.

Authors:  Patricia J M Best; Peter B Berger; Barry R Davis; Cindy L Grines; H Mehrdad Sadeghi; Brent A Williams; James T Willerson; Jeffrey R Granett; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

6.  Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease.

Authors:  Donal N Reddan; Lynda Anne Szczech; Robert H Tuttle; Linda K Shaw; Robert H Jones; Steve J Schwab; Mark Stafford Smith; Robert M Califf; Daniel B Mark; William F Owen
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

7.  Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients.

Authors:  Sen Yachi; Kengo Tanabe; Shuzou Tanimoto; Jiro Aoki; Gaku Nakazawa; Hirosada Yamamoto; Shuji Otsuki; Atsuhiko Yagishita; Satoru Kishi; Masataka Nakano; Masahiro Taniwaki; Shunsuke Sasaki; Hiroyoshi Nakajima; Naofumi Mise; Tokuichiro Sugimoto; Kazuhiro Hara
Journal:  Am J Kidney Dis       Date:  2009-04-25       Impact factor: 8.860

8.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

9.  Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents.

Authors:  Pramod K Kuchulakanti; Rebecca Torguson; William W Chu; Daniel A Canos; Seung-woon Rha; Leonardo Clavijo; Regina Deible; Natalie Gevorkian; William O Suddath; Lowell F Satler; Kenneth M Kent; Augusto D Pichard; Ron Waksman
Journal:  Am J Cardiol       Date:  2006-01-18       Impact factor: 2.778

10.  Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.

Authors:  Young-Hoon Jeong; Myeong-Ki Hong; Cheol Whan Lee; Duk-Woo Park; Young-Hak Kim; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Int J Cardiol       Date:  2007-05-22       Impact factor: 4.164

View more
  14 in total

1.  Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up.

Authors:  Alessandro Cuneo; Peter Bramlage; Matthias Hochadel; Jochen Senges; Christoph Nienaber; Karl-Heinz Kuck; Ulrich Tebbe
Journal:  Clin Res Cardiol       Date:  2011-12-09       Impact factor: 5.460

2.  Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function.

Authors:  Barbara E Stähli; Cathérine Gebhard; Michael Gick; Miroslaw Ferenc; Kambis Mashayekhi; Heinz Joachim Buettner; Franz-Josef Neumann; Aurel Toma
Journal:  Clin Res Cardiol       Date:  2017-11-13       Impact factor: 5.460

3.  Large-scale experience with an anchorless vascular closure device in a real-life clinical setting.

Authors:  Verena Schelp; Sandra Freitag-Wolf; Dieter Hinzmann; Peter Bramlage; Norbert Frey; Derk Frank
Journal:  Clin Res Cardiol       Date:  2014-10-08       Impact factor: 5.460

4.  Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.

Authors:  Omar K Siddiqi; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; Melissa Young; David R Gagnon; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay
Journal:  Heart       Date:  2015-07-24       Impact factor: 5.994

5.  Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.

Authors:  Gjin Ndrepepa; Franz-Josef Neumann; Salvatore Cassese; Massimiliano Fusaro; Ilka Ott; Stefanie Schulz; Petra Hoppmann; Gert Richardt; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2013-10-04       Impact factor: 5.460

6.  TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention.

Authors:  Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf
Journal:  Clin Res Cardiol       Date:  2012-05-06       Impact factor: 5.460

7.  Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application.

Authors:  Christoph Sinning; Lars Lillpopp; Sebastian Appelbaum; Francisco Ojeda; Tanja Zeller; Renate Schnabel; Edith Lubos; Annika Jagodzinski; Till Keller; Thomas Munzel; Christoph Bickel; Stefan Blankenberg
Journal:  Clin Res Cardiol       Date:  2013-03-23       Impact factor: 5.460

8.  Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.

Authors:  Jens Wiebe; Helge Möllmann; Astrid Most; Oliver Dörr; Kay Weipert; Johannes Rixe; Christoph Liebetrau; Albrecht Elsässer; Stephan Achenbach; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2013-10-18       Impact factor: 5.460

9.  Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial.

Authors:  Heli M Lahtela; Tuomas O Kiviniemi; Marja K Puurunen; Axel Schlitt; Andrea Rubboli; Antti Ylitalo; José Valencia; Gregory Y H Lip; K E Juhani Airaksinen
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

10.  Cardiac arrest during percutaneous coronary intervention in a patient 'resistant' to clopidogrel - successful 50-minute mechanical chest compression.

Authors:  Marcin Protasiewicz; Pawel Szymkiewicz; Krzysztof Sciborski; Alina Orda; Bozena Karolko; Anna Jonkisz; Arleta Lebioda; Andrzej Mysiak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-11-18       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.